Selected article for: "clinical laboratory and infectious disease"
Author: Kim, Jee-Eun; Heo, Jae-Hyeok; Kim, Hye-ok; Song, Sook-hee; Park, Sang-Soon; Park, Tai-Hwan; Ahn, Jin-Young; Kim, Min-Ky; Choi, Jae-Phil
Title: Neurological Complications during Treatment of Middle East Respiratory Syndrome
  • Cord-id: 0wgafqdz
  • Document date: 2017_6_30
    • ID: 0wgafqdz
    Snippet: BACKGROUND AND PURPOSE: Middle East respiratory syndrome (MERS) has a high mortality rate and pandemic potential. However, the neurological manifestations of MERS have rarely been reported since it first emerged in 2012. METHODS: We evaluated four patients with laboratory-confirmed MERS coronavirus (CoV) infections who showed neurological complications during MERS treatment. These 4 patients were from a cohort of 23 patients who were treated at a single designated hospital during the 2015 outbre
    Document: BACKGROUND AND PURPOSE: Middle East respiratory syndrome (MERS) has a high mortality rate and pandemic potential. However, the neurological manifestations of MERS have rarely been reported since it first emerged in 2012. METHODS: We evaluated four patients with laboratory-confirmed MERS coronavirus (CoV) infections who showed neurological complications during MERS treatment. These 4 patients were from a cohort of 23 patients who were treated at a single designated hospital during the 2015 outbreak in the Republic of Korea. The clinical presentations, laboratory findings, and prognoses are described. RESULTS: Four of the 23 admitted MERS patients reported neurological symptoms during or after MERS-CoV treatment. The potential diagnoses in these four cases included Bickerstaff's encephalitis overlapping with Guillain-Barré syndrome, intensive-care-unit-acquired weakness, or other toxic or infectious neuropathies. Neurological complications did not appear concomitantly with respiratory symptoms, instead being delayed by 2–3 weeks. CONCLUSIONS: Neuromuscular complications are not rare during MERS treatment, and they may have previously been underdiagnosed. Understanding the neurological manifestations is important in an infectious disease such as MERS, because these symptoms are rarely evaluated thoroughly during treatment, and they may interfere with the prognosis or require treatment modification.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and loading dose: 1
    • acute ards respiratory distress syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
    • acute ards respiratory distress syndrome and lopinavir ritonavir ribavirin: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and low respiratory tract: 1, 2
    • acute ards respiratory distress syndrome and lumbar puncture: 1, 2
    • acute ards respiratory distress syndrome and lung heart: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
    • acute ards respiratory distress syndrome and lung heart disease: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and magnetic resonance: 1, 2, 3, 4, 5, 6
    • acute physiology score ii and admission prior: 1
    • acute physiology score ii and loading dose: 1
    • acute physiology score ii and lopinavir ritonavir: 1
    • acute physiology score ii and lopinavir ritonavir lr intravenous immunoglobulin: 1
    • acute physiology score ii and lr intravenous immunoglobulin: 1
    • acute physiology score ii and lung heart: 1, 2
    • acute physiology score ii and lung heart disease: 1, 2
    • acute respiratory failure and admission prior: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory failure and loading dose: 1
    • acute respiratory failure and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory failure and lopinavir ritonavir ribavirin: 1, 2